H
Harry Qin
Publications - 2
Citations - 109
Harry Qin is an academic researcher. The author has contributed to research in topics: Melanoma & Median follow-up. The author has an hindex of 2, co-authored 2 publications receiving 13 citations.
Papers
More filters
Journal ArticleDOI
Lifileucel, a Tumor-Infiltrating Lymphocyte Therapy, in Metastatic Melanoma.
Amod A. Sarnaik,Omid Hamid,Nikhil I. Khushalani,Karl D. Lewis,Theresa Medina,Harriet M. Kluger,Sajeve Samuel Thomas,Evidio Domingo-Musibay,Anna C. Pavlick,Eric D. Whitman,Salvador Martín-Algarra,Pippa Corrie,Brendan D. Curti,Judit Oláh,Jose Lutzky,Jeffrey S. Weber,James Larkin,Wen Shi,Toshimi Takamura,Madan Jagasia,Harry Qin,Xiao Wu,Cecile Chartier,Friedrich Graf Finckenstein,Maria Fardis,John M. Kirkwood,Jason Chesney +26 more
TL;DR: In this article, the authors discuss the limitations of existing treatment options for patients with advanced melanoma who progress after immune checkpoint inhibitors and targeted therapies, and propose an adaptive cell-based approach.
Journal ArticleDOI
P865 Safety & efficacy of lifileucel (LN-144) tumor infiltrating lymphocyte therapy in metastatic melanoma patients after progression on multiple therapies – independent review committee data update
Amod A. Sarnaik,Nikhil I. Khushalani,Jason Chesney,Harriet M. Kluger,Brendan D. Curti,Karl D. Lewis,Theresa Medina,Sajeve Samuel Thomas,Anna C. Pavlick,Eric D. Whitman,Salvador Algarra,Pippa Corrie,Omid Hamid,Jose Lutzky,Judit Oláh,Jeffrey S. Weber,James Larkin,Wen Shi,Kelly DiTrapani,Harry Qin,Mariam Mirgoli,Renee Wu,Toshimi Takamura,Maria Fardis,John M. Kirkwood +24 more
TL;DR: Lifileucel treatment resulted in a 36.4% ORR in heavily pretreated metastatic melanoma patients with high baseline disease burden who had received prior anti-PD1 and BRAF/MEK inhibitors, if tumor BRAF mutated.